
    
      A total of up to 390 patients â‰¤ 65 years old diagnosed of Multiple Myeloma with symptomatic
      disease and that have not received previous chemotherapy for MM will be included.

      Patients will be evaluated at scheduled visits in up to three study periods: Pre-treatment,
      Treatment and Follow up.

      The Pre-treatment includes Screening and baseline visits. After providing informed consent,
      patients will be evaluated for study eligibility and then Patients will be randomized (1:1:1)
      to receive VBMCP-VBAD+Velcade (Group A) or Thalidomide+Dexamethasone (Group B) or
      Thalidomide+Dexamethasone+Velcade (Group C). All of them will received the induction
      treatment up to 24 weeks.

      After 4 weeks, without progression or unacceptable toxicity, There will be stem cell
      mobilization to do an autologous transplant. Three months after transplant, patients will be
      again randomized (1:1:1) to receive maintenance treatment: Interferon-a (Group M1) or
      Thalidomide (Group M2) or Thalidomide+Velcade (Group M3) during three years.

      Once the treatment period has finished a follow up will be carry out. During this period we
      will evaluated response, progression-free survival and global survival every three months.
    
  